Successful Management of Kaposiform Hemangioendothelioma with Kasabach‐Merritt Phenomenon Using Vincristine and Ticlopidine

López, Vicente Navarro; Martí, Nuria; Pereda, Carolina; Martín, J.M.; Ramón, Dolores; Mayordomo, Émpar; Jordá, Esperanza

doi:10.1111/j.1525-1470.2009.00923.x

Cited by 31 publications

(27 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Being a vesicant, it is recommended to be given intravenously via central venous line at 1-2 mg/m 2 per week [19,29,30,53,[58][59][60]. In one case series, the average time for platelet recovery was two months, and the average time for hemangioma regression was four months [31].…”

Section: Vincristinementioning

confidence: 99%

“…In a case series involving 11 patients, vincristine in combination with aspirin and ticlopidine [19,51,60] demonstrated excellent clinical response, and this response was quicker than vincristine alone [63]. The response rate of vincristine when used with steroids approaches 78% [30]. In 2013, an expert panel recommended steroids and vincristine as first-line treatment for KMS [64].…”

Section: Vincristinementioning

confidence: 99%

“…The general approach is to manage coagulopathy effectively with supportive care and medical management [23][24][25][26][27][28][29][30] …”

Section: Managementmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Review: Management of Adult Kasabach-Merritt Syndrome Associated with Hemangiomas

Master¹,

Kallam²,

Eo³

et al. 2017

J Blood Disord Transfus

View full text Add to dashboard Cite

Kasabach-Merritt syndrome (KMS) consists of a clinical trial of capillary hemangioma, thrombocytopenia and disseminated intravascular coagulation. KMS occurs most commonly in the pediatric population, and its occurrence in adults is rare. Specific guidelines or randomized clinical trials guiding clinical management of KMS in adult patients are lacking. This manuscript provides a comprehensive review of KMS and discusses recent advances in the medical management of KMS. We also propose a systematic therapeutic approach which would serve as a guide in the management of adult patients with KMS caused by hemangiomas.

show abstract

Section: Vincristinementioning

confidence: 99%

Section: Vincristinementioning

confidence: 99%

See 1 more Smart Citation

Clinical Review: Management of Adult Kasabach-Merritt Syndrome Associated with Hemangiomas

Master¹,

Kallam²,

Eo³

et al. 2017

J Blood Disord Transfus

View full text Add to dashboard Cite

show abstract

“…[11,[13][14][15]. Only a few previous studies have shown the benefits of adjuvant chemotherapy, and the results were highly estimated.…”

Section: Discussionmentioning

confidence: 63%

Soft Tissue Hemangioendothelioma in Children

Youn

Jung

Kim

et al. 2017

J Korean Assoc Pediatr Surg

View full text Add to dashboard Cite

Purpose: Soft tissue hemangioendothelioma (STHE) is a rare vascular tumor, which has a similar prognosis to borderline malignancy. The disease is poorly understood in pediatric cases because of its low incidence; therefore, we investigated treatment strategies for STHE in children. Methods: We retrospectively analyzed 8 patients with STHE, who were pathologically confirmed between January 1995 and June 2015. The median duration of follow-up was 72 months. Results: Five were male and the median age at the time of surgery was 1.2 years. Six patients presented with a palpable mass, and 2 patients experienced facial paralysis. The median tumor size was 4.0 cm. The following tumor locations were observed head (2 patients), neck (2 patients), chest wall (1 patient), sacrococcyx (1 patient), upper limb (1 patient), and lower limb (1 patient). The patients underwent either microscopic complete resection (R0) (3 patients), macroscopic complete resection (R1) (2 patients), or macroscopic incomplete resection (R2) (3 patients). After histopathological examination, 6 patients were diagnosed with kaposiform hemangioendothelioma (HE), one with retiform HE, and one with epithelioid HE. Postoperative sequelae occurred as gait disturbance, hearing impairment, and vocal cord palsy. Tumor recurrence or regrowth occurred in 4 patients. These patients underwent reoperation and IFN therapy; however, in the patient with epithelioid HE, metastasis to the scalp occurred after these therapies. The patient with the head tumor who underwent R2 resection, underwent resection three more times, but died 11 months after the first surgery. Conclusion: When treating STHE in children, R0 resection should be first considered, but recurrence and metastasis should be monitored depending on the size, pathology, and location of the lesion. When major sequelae are expected, function-preserving surgery could be considered, depending on tumor location, size, and nearby organs.

show abstract

“…La resección es el tratamiento definitivo, lo que frecuentemente no es posible por complicaciones hemorrágicas severas 7 . Se han intentado múltiples tratamientos médicos: corticoides, vincristina, interferón-g, quimioterapia combinada, embolización, propanolol, escleroterapia y radioterapia, con eficacia variable, no existiendo consenso sobre el tratamiento de elección [1][2][3]6,[8][9][10] . En los últimos años, Sirolimus (Rapamicina) un inhibidor del mTOR (mammalian target of rapamycin), ha mostrado ser efectivo en el tratamiento de anomalías vasculares, evidenciando una importante actividad antiangiogénica.…”

Section: Introductionunclassified

Sirolimus (rapamicina) en pacientes con hemangioendotelioma kaposiforme: Caso clínico

2013

Rev. chil. pediatr.

View full text Add to dashboard Cite

Successful Management of Kaposiform Hemangioendothelioma with Kasabach‐Merritt Phenomenon Using Vincristine and Ticlopidine

Cited by 31 publications

References 6 publications

Clinical Review: Management of Adult Kasabach-Merritt Syndrome Associated with Hemangiomas

Clinical Review: Management of Adult Kasabach-Merritt Syndrome Associated with Hemangiomas

Soft Tissue Hemangioendothelioma in Children

Sirolimus (rapamicina) en pacientes con hemangioendotelioma kaposiforme: Caso clínico

Contact Info

Product

Resources

About